Last defendant in Polar Air Cargo fraud case convicted
Polar Air Cargo no longer exists, but the people involved in a scheme to defraud the airline of $32 million are still paying the price.
The U.S. government on Thursday announced the latest sentencing in the case. Skye Xu was sentenced to two years in prison by U.S. District Judge Jesse Furman for paying around $4.4 million in kickbacks in a nine-month span starting in November 2020 to shell companies controlled by three senior Polar executives.
The kickbacks earned Xu and his California-based Sky X Airlines, an airfreight wholesaler, two lucrative business contracts with Polar, according to court records. The contracts earned Sky X Airlines about $46 million in gross revenue and nearly $10 million in net revenue based on the sales of unused cargo space during the COVID pandemic.
Xu previously pleaded guilty to conspiracy to commit wire fraud and money laundering.
In total, the Polar executives received more than $20 million in kickbacks and other financial benefits from Polar customers and vendors over a dozen years in exchange for favorable business arrangements with Polar. Kickback payments were often calculated per kilo of cargo shipped with Polar or as a percentage of the revenue earned as a result of the vendor's relationship with Polar.
'The fraud that Xu and his coconspirators perpetrated – which involved a substantial portion of Polar's senior management and at least ten customers and vendors of Polar – led to pervasive corruption of Polar's business, touching nearly every aspect of the company's operations, for over a decade,' the U.S. Attorney's Office for the Southern District of New York said in a news release.
The senior Polar executives also reaped substantial benefits as a result of secret ownership interests in some of the company's vendors.
Xu was the last of 10 defendants charged in this case to be convicted. Five of the 10 charged defendants have previously been sentenced. In addition to the prison term, Xu was sentenced to three years of supervised release and ordered to forfeit $4.5 million and make restitution to Polar in the amount of $1.4 million.
In October, Abilash Kurien, a former vice president of marketing, revenue management and network planning at Polar Air Cargo, was sentenced to two years and eight months in prison. Carlton Llewellyn, who served as Polar's vice president in charge of operations systems performance and quality, was sentenced to six months in prison. In late August, Robert Schirmer, who was senior director of customer service for the Americas at Polar, received an 18-month prison sentence.
The ringleader of the scheme was Lars Winkelbauer, Polar's chief operating officer for three years until July 2021. Winkelbauer joined DHL from Polar in 2007 and, in an unusual arrangement, the courier allowed him to hold dual leadership positions at both companies. Between 2014 and 2018, he served as DHL's vice president for aviation and network planning in the Asia Pacific region and had a similar role at Polar. In May 2024, he was sentenced to four years in federal prison.
During the first quarter, Atlas Air and DHL Express shut down their Polar Air Cargo joint venture after 18 years. Atlas Air operated the aircraft and sold unused DHL capacity to freight forwarders. Last year, Polar Air Cargo had eight widebody freighters in its fleet, according to aviation databases.
The companies said ending their partnership was a mutual decision, but DHL executives said during a March earnings call with investors that the company is streamlining its list of contract carriers as part of a sweeping cost-cutting campaign.
Click here for more FreightWaves/American Shipper stories by Eric Kulisch.
Atlas Air, DHL terminate Polar Air Cargo joint venture
DHL cuts ties with cargo airlines as efficiency initiative ramps up
Another Polar executive gets time behind bars
The post Last defendant in Polar Air Cargo fraud case convicted appeared first on FreightWaves.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development
LAS VEGAS, June 4, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the Company is in the final stages of prototyping its proprietary automated retinal camera. Ainnova's new device will offer users a low cost, easier to use camera that captures images automatically and then uploads those images to the Company's Vision AI software platform, which then produces a "risk report" in mere seconds. Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said, "The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market. "Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists. Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach." Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration, and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova has integrated into the software like the detection of cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD). Currently, Ainnova's Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera. Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova's technology portfolio. AAC owns the global licensing rights to develop, maintain, and market Ainnova's technology portfolio. About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release. Contact:Avant Technologies, Inc. info@ View original content to download multimedia: SOURCE Avant Technologies Inc.
Yahoo
30 minutes ago
- Yahoo
Mindset Medical Announces FDA Clearance for its Contactless Respiratory Rate Measurement Device
PHOENIX, June 4, 2025 /PRNewswire/ -- Mindset Medical, Inc. ("Mindset Medical" or the "Company"), a digital health company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its latest contactless vital sign monitoring solution. The Informed Vital Core (IVC) App is a software-only medical device that measures respiratory rate through smartphones, tablets, or laptop cameras. This milestone marks Mindset Medical's second FDA clearance in less than a year, building on the success of its previously cleared pulse rate measurement device on November 18, 2024. With these clearances, Mindset Medical is closer to transforming the delivery of care with innovative telehealth technology. Mindset Medical can now offer another solution for healthcare providers to gather physiological information from their patients without needing physical contact or dedicated hardware. Software on phones, tablets, and laptops can easily be deployed in clinical and outpatient facilities, remote care environments, long-term care settings, or the patient's home. Telemedicine skyrocketed due to COVID-19, as many barriers to adoption were removed, allowing video conferencing to become routine. "Video alone is not enough. Patients and providers deserve virtual services with fewer barriers and limitations because we are all patients at the end of the day. The next step is purpose-built virtual health offerings that can legitimately provide brick-and-mortar experiences. Virtual healthcare remains a permanent fixture moving forward, and we have only scratched the surface of how we use technology to address shortcomings with the health system."-- Mitch Foster, Chairman and CEO of Mindset Medical. Mindset Medical envisions a future where vital signs and diagnoses can be captured with nothing more than everyday devices. This will help bridge gaps in access to healthcare, reduce the burden on providers, and improve chances for earlier intervention. The company continues developing its platform to include additional vital sign measurements, working closely with clinicians and patients to ensure each new feature meets their needs. About Mindset Medical Mindset Medical, Inc. ( headquartered in Phoenix, AZ, was formed by several members of Excelsius Surgical, a robotic surgical platform. Recently, Mindset Medical has developed proprietary signal-processing algorithms that extract health measurements from video. Combined with AI technology for advanced image analysis and facial recognition, these algorithms transform patients' smartphones into contactless vital sign measurement devices. Mindset Medical utilizes secure and encrypted links delivered to patients from healthcare providers to collect up-to-the-minute patient data and accurate remote physiological measurements. Contact For media, sales, or investor inquiries, please email 396163@ or 396163@ We can also be reached at 480.269.0859. HASHTAGS#healthcare #telehealth #healthequity #vitals #physiological SOCIAL MEDIA PROFILESLinkedin: View original content: SOURCE Mindset Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla., June 4, 2025 /CNW/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina-based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The acquisition represents a key step in Continuity's strategy to become a leader in device targeted therapeutics for intractable solid tumors. Founded by leading scientists and clinicians, Focal Medical has developed a proprietary platform that delivers chemotherapy directly to tumors using iontophoresis—this minimally-invasive technique utilizes a mild electrical current to drive therapeutic compounds into targeted tissues. This method enhances local drug concentration while minimizing systemic toxicity, a critical need in the treatment of pancreatic and other solid-tissue cancers. Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been cleared by the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. Phase 1b clinical trials are expected to begin later this year. "This is a transformative milestone for Continuity Biosciences," said Ramakrishna Venugopalan, PhD, MBA, Chief Executive Officer of Continuity Biosciences. "Focal Medical's approach to localized drug delivery aligns perfectly with our vision to improve bioavailability, reduce systemic exposure, and deliver better outcomes for patients. We are thrilled to bring this promising platform into our portfolio and into the clinic." Through the acquisition, Continuity Biosciences obtains Focal Medical's entire patent estate, iontophoresis technology platform and specialized equipment, scientific know-how, and licensing agreements with the University of North Carolina at Chapel Hill. In addition, key scientific staff and leadership from Focal will join Continuity, further enhancing its internal capabilities. A dedicated research and development facility in Cary, NC that supports ongoing platform and pipeline advancement is also part of the acquisition and will be expanded to support other delivery platforms. Visionary Founders Driving the Innovation Focal Medical was co-founded by: Jen Jen Yeh, MD, a surgical oncologist and professor at UNC-Chapel Hill with joint appointments in Surgery and Pharmacology. She serves as assistant dean of translational research in UNC School of Medicine and associate director of translational research in UNC Lineberger Comprehensive Cancer Center. Dr. Yeh is widely recognized for her expertise in pancreatic cancer and translational oncology. Joseph DeSimone, PhD, an award-winning chemist, entrepreneur, and academic, currently serving as the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. He is globally known for his breakthroughs in materials science, nanomedicine, and advanced manufacturing, including 3D printing. Their iontophoresis system is designed to deliver gemcitabine, an FDA-approved chemotherapy agent, directly into pancreatic tumors. Traditional systemic administration of gemcitabine is often limited by poor tumor penetration and significant toxicity. Focal's approach bypasses those limitations by delivering the drug directly to the tumor site with high precision and minimal systemic toxicity. "After nearly a decade of R&D, we are excited to join the Continuity Biosciences family," said Tony Voiers, Acting CEO of Focal Medical. "We are grateful to our founders, scientific collaborators, and investors who have helped us reach this pivotal point. Partnering with Continuity ensures that this novel therapy moves forward into the clinic where it has the potential to help patients facing one of the deadliest cancers." This acquisition reinforces Continuity Biosciences' commitment to building a diverse portfolio of clinically meaningful drug delivery platforms and signals a decisive move toward becoming a clinical-stage leader in site-specific therapy. About Continuity BiosciencesContinuity Biosciences, LLC is a biopharmaceutical company developing advanced drug delivery technologies that address the limitations of conventional therapeutic administration. With operations in Bradenton, FL; Houston, TX; Raleigh, NC; and Torino, Italy, the company focuses on combination drug-device platforms for chronic and complex About Focal MedicalFocal Medical, Inc. develops energy-based chemotherapy delivery systems that enable direct application of drugs to tumor sites. Its mission is to improve efficacy and reduce toxicity in the treatment of solid tumors, with an initial focus on pancreatic View original content to download multimedia: SOURCE Continuity Biosciences LLC View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data